ENSC: 分析师目标 $16 — AI 分析 (4月 2026)

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing novel pain relief and overdose protection technologies. Their innovative platforms aim to address opioid misuse and abuse, offering potential solutions for severe pain management and opioid use disorder.

Key Facts: Price: $0.55 Analyst Target: $16.45 AI Score: 60/100 Sector: Healthcare

公司概况

概要：

Ensysce Biosciences is pioneering next-generation pain management solutions with its TAAP and MPAR platforms, targeting opioid abuse and overdose. With a focus on developing safer and more effective pain relief options, ENSC offers a notable market position in the evolving pharmaceutical landscape, despite its current financial challenges.

ENSC是做什么的？

Ensysce Biosciences, Inc., founded in 2003 and headquartered in La Jolla, California, is a clinical-stage pharmaceutical company dedicated to developing innovative prescription drugs for severe pain relief while mitigating the risks of opioid misuse, abuse, and overdose. The company's core technology revolves around two primary platforms: Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR). The TAAP platform is designed to ensure that drugs are only released when exposed to specific physiological conditions, reducing the potential for abuse. The MPAR platform, on the other hand, is an overdose protection opioid prodrug technology aimed at preventing fatal overdoses. Ensysce's lead product candidate, PF614, is a TAAP oxycodone prodrug intended for the treatment of severe or chronic pain. Additionally, the company is developing PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. Beyond pain management, Ensysce is also exploring treatments for attention deficit hyperactivity disorder (ADHD) with PF8001 and PF8026, extended and immediate-release prodrugs of amphetamine, respectively, and PF9001 to treat Opioid use disorder. As a clinical-stage company, Ensysce is focused on advancing its pipeline through clinical trials and seeking regulatory approvals to bring its innovative therapies to market.

ENSC的投资论点是什么？

Investing in Ensysce Biosciences presents a high-risk, high-reward opportunity in the pharmaceutical sector. The company's innovative TAAP and MPAR platforms address a critical need for safer pain management solutions, potentially disrupting the opioid market. The primary value driver is the successful clinical development and regulatory approval of PF614 and PF614-MPAR. Upcoming milestones include clinical trial results and potential FDA submissions. While the company's negative profit margin of -244.5% and gross margin of -93.4% reflect its current clinical-stage status, successful commercialization could lead to significant revenue growth and market share capture. The company's small market cap makes it highly speculative, but the potential for breakthrough therapies in pain management warrants consideration for risk-tolerant investors.

ENSC在哪个行业运营？

Ensysce Biosciences operates within the biotechnology industry, specifically targeting the pain management and addiction treatment markets. The opioid crisis has created a significant demand for safer and more effective pain relief options with abuse-deterrent properties. The competitive landscape includes companies developing non-opioid pain medications and abuse-deterrent formulations of existing opioids. Ensysce's TAAP and MPAR platforms offer a unique approach by utilizing prodrug technology to control drug release and prevent overdose. The market for pain management is substantial, with chronic pain affecting millions of people worldwide, creating a significant opportunity for innovative therapies.

Biotechnology

Healthcare

ENSC有哪些增长机遇？

FDA Approval and Commercialization of PF614: The successful completion of clinical trials and subsequent FDA approval of PF614 for severe pain could unlock a substantial market opportunity. The market for opioid pain relievers is estimated to be billions of dollars annually, and a safer, abuse-deterrent formulation could capture a significant share. Timeline: Potential FDA submission within the next 1-2 years, pending clinical trial results.
Advancement of PF614-MPAR for Overdose Protection: The development and approval of PF614-MPAR could address the critical need for overdose protection in opioid prescriptions. Government initiatives and public health concerns are driving demand for such products. Timeline: Concurrent with PF614 development, with potential for expedited approval pathways.
Expansion into ADHD Treatment with PF8001 and PF8026: Ensysce's development of amphetamine prodrugs for ADHD offers a diversification opportunity beyond pain management. The ADHD market is growing, with increasing diagnosis rates and demand for effective treatments. Timeline: Pre-clinical and early clinical development stages, with potential for clinical trials in the next 2-3 years.
Partnerships and Licensing Agreements: Ensysce could pursue partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its products. Licensing agreements could provide upfront payments and royalties, strengthening the company's financial position. Timeline: Ongoing, with potential for agreements in the near term.
Development of PF9001 for Opioid Use Disorder: Addressing the opioid crisis by developing a treatment for opioid use disorder. The market size is substantial, driven by the urgent need for effective addiction therapies. Timeline: Pre-clinical development, with potential for clinical trials in the next 3-4 years.

Developing PF614, a TAAP oxycodone prodrug candidate, targeting a safer approach to severe and chronic pain management.
Advancing PF614-MPAR, a combination product for overdose protection, addressing a critical need in opioid safety.
Utilizing the Trypsin Activated Abuse Protection (TAAP) platform, designed to reduce the potential for drug abuse.
Employing the Multi-Pill Abuse Resistance (MPAR) platform, an overdose protection opioid prodrug technology.
Exploring treatments for ADHD and Opioid Use Disorder with PF8001, PF8026 and PF9001, expanding the pipeline beyond pain management.

ENSC提供哪些产品和服务？

Develop prescription drugs for severe pain relief.
Create products to combat opioid misuse and abuse.
Utilize the Trypsin Activated Abuse Protection (TAAP) platform for safer drug release.
Employ the Multi-Pill Abuse Resistance (MPAR) platform for overdose protection.
Develop prodrugs for attention deficit hyperactivity disorder (ADHD).
Research treatments for Opioid Use Disorder.

ENSC如何赚钱？

Develops and patents proprietary drug formulations.
Conducts clinical trials to demonstrate safety and efficacy.
Seeks regulatory approval from the FDA.
Aims to commercialize products through partnerships or direct sales (future).

Patients suffering from severe or chronic pain.
Individuals with attention deficit hyperactivity disorder (ADHD).
Patients struggling with opioid use disorder.
Healthcare providers prescribing pain medication and addiction treatment.

Proprietary TAAP and MPAR technology platforms.
Patent protection for drug formulations and delivery systems.
First-mover advantage in developing abuse-deterrent opioid prodrugs.
Potential for regulatory exclusivity upon FDA approval.

什么因素可能推动ENSC股价上涨？

Upcoming: Clinical trial results for PF614 and PF614-MPAR.
Upcoming: FDA submission for PF614 and PF614-MPAR.
Ongoing: Progress in pre-clinical development of PF8001, PF8026 and PF9001.
Ongoing: Potential partnerships and licensing agreements.

ENSC的主要风险是什么？

Potential: Clinical trial failures and regulatory rejections.
Potential: Dilution risk from future funding needs.
Ongoing: Competition from established pharmaceutical companies.
Ongoing: Dependence on key personnel and intellectual property.

ENSC的核心优势是什么？

Innovative TAAP and MPAR technology platforms.
Potential to address the opioid crisis with safer pain relief options.
Pipeline of drug candidates targeting multiple indications.
Strong intellectual property protection.

ENSC的劣势是什么？

Clinical-stage company with no currently approved products.
Negative profit and gross margins.
Reliance on successful clinical trial outcomes and regulatory approvals.
Limited financial resources and potential need for further funding.

ENSC有哪些机遇？

FDA approval and commercialization of PF614 and PF614-MPAR.
Partnerships with larger pharmaceutical companies.
Expansion into new therapeutic areas, such as ADHD.
Government grants and funding for opioid abuse prevention.

ENSC面临哪些威胁？

Competition from established pharmaceutical companies.
Regulatory hurdles and potential for clinical trial failures.
Patent challenges and intellectual property infringement.
Changes in government regulations and healthcare policies.

ENSC的竞争对手是谁？

AIM ImmunoTech Inc. — Focuses on immune-modulating therapies. — (AIM)
Can-Fite BioPharma Ltd — Develops drugs for inflammatory and liver diseases. — (CANF)
Kala Pharmaceuticals Inc — Develops therapies for eye diseases. — (KALA)
Kazia Therapeutics Ltd — Develops oncology drugs. — (KZIA)
OGEN — Focuses on developing treatments for infectious diseases. — (OGEN)

Key Metrics

Price: $0.55 (-2.98%)
Market Cap: $2.0M
MoonshotScore: 60/100

Analyst Price Target

Analyst Consensus Target: $16.45
Current Price: $0.55
Implied Upside: +2907.3%

常见问题

What does Ensysce Biosciences, Inc. (ENSC) do?

Ensysce Biosciences, Inc. (ENSC) is a clinical-stage pharmaceutical company focused on developing innovative solutions for pain management and overdose prevention. They utilize their proprietary TAAP and MPAR platforms to create safer and more effective pain relief medications, aiming to reduce the risks of opioid misuse, abuse, and overdose. Their lead product candidates target severe pain and opioid use disorder, addressing a critical need in the healthcare industry.

Is ENSC stock a good buy?

ENSC stock presents a speculative investment opportunity due to its clinical-stage nature and lack of revenue. While the company's innovative technology and potential to disrupt the pain management market are promising, the may be worth researching high risks associated with clinical trials, regulatory approvals, and the company's current financial position. A negative profit margin and the need for future funding add to the uncertainty, making it suitable only for risk-tolerant investors.

What are the main risks for ENSC?

The primary risks for Ensysce Biosciences include the potential for clinical trial failures, which could significantly impact the company's valuation. Regulatory hurdles and the possibility of not receiving FDA approval for its drug candidates also pose substantial risks. Additionally, the company faces dilution risk as it may need to raise further capital to fund its operations, potentially diluting existing shareholders' ownership. Competition from larger pharmaceutical companies with greater resources is another ongoing risk.

What catalysts could move ENSC stock?

Several catalysts could potentially move ENSC stock. Positive clinical trial results for PF614 and PF614-MPAR would be a significant catalyst, demonstrating the efficacy and safety of their drug candidates. The submission of New Drug Applications (NDAs) to the FDA and subsequent approval decisions could also drive the stock price higher. Furthermore, any partnerships or licensing agreements with larger pharmaceutical companies could provide financial validation and boost investor confidence.

What is ENSC stock price target?

As of March 3, 2026, there is no readily available analyst consensus price target for ENSC stock due to its micro-cap status and limited analyst coverage. A fair value estimate would require a detailed discounted cash flow (DCF) analysis, considering the potential future revenues from its drug candidates, the probability of regulatory approval, and the company's cost of capital. Investors should conduct their own due diligence and consider the inherent risks before making any investment decisions.